-
![Pyrrolo[2,3-D]pyrimidine derivatives](/abs-image/US/2017/01/17/US09545405B2/abs.jpg.150x150.jpg)
公开(公告)号：US09545405B2
公开(公告)日：2017-01-17
申请号：US14691606
申请日：2015-04-21
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez , Mihir D. Parikh
IPC: A01N43/90 , A61K31/519 , C07D487/00 , C07D487/04 , C07D519/00 , A61K31/5386 , C07D207/18
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
-
![PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES](/abs-image/US/2015/09/03/US20150246048A1/abs.jpg.150x150.jpg)
公开(公告)号：US20150246048A1
公开(公告)日：2015-09-03
申请号：US14715046
申请日：2015-05-18
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez , Mihir D. Parikh
IPC: A61K31/519 , A61K31/5386
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物，它们用作Janus Kinase（JAK）抑制剂，以及含有它们的药物组合物。
-
公开(公告)号：US20180273504A1
公开(公告)日：2018-09-27
申请号：US15547228
申请日：2016-01-29
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand J. Unwalla
IPC: C07D401/04 , A61P29/00 , A61P37/06 , C07D401/14 , C07D417/14 , C07D405/14 , C07D413/14
CPC classification number: C07D401/04 , A61P29/00 , A61P37/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
-
公开(公告)号：US09458168B2
公开(公告)日：2016-10-04
申请号：US14678114
申请日：2015-04-03
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D207/26 , C07D401/12 , A61K31/44 , C07D491/056 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D215/48 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , C07F7/18
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![Pyrrolo[2,3-D]pyrimidine derivatives](/abs-image/US/2015/05/19/US09035074B2/abs.jpg.150x150.jpg)
公开(公告)号：US09035074B2
公开(公告)日：2015-05-19
申请号：US14183946
申请日：2014-02-19
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez , Mihir D. Parikh
IPC: C07D207/18 , C07D487/04 , C07D519/00
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物，它们用作Janus Kinase（JAK）抑制剂，以及含有它们的药物组合物。
-
Patent Agency Ranking
公开(公告)号：US10793579B2
公开(公告)日：2020-10-06
申请号：US16411679
申请日：2019-05-14
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D401/14 , A61K31/47 , A61K31/4709 , A61K31/4725 , C07D491/056 , C07F7/18 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10426135B2
公开(公告)日：2019-10-01
申请号：US16268857
申请日：2019-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A01K5/01 , B65D77/20 , B65D25/04 , B65D1/34 , A01K7/00 , A23K20/00 , A23K50/48 , B65D1/36 , B65D25/18 , B65D85/00
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US20180127432A1
公开(公告)日：2018-05-10
申请号：US15862691
申请日：2018-01-05
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , C07D239/88 , C07D239/86 , C07D263/24 , C07D207/267 , A61K31/40 , C07D207/08 , C07F7/18 , C07D209/52 , C07D498/04 , C07D207/273 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D407/14 , C07D215/48 , C07D207/26 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61K31/4015
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20160347760A1
公开(公告)日：2016-12-01
申请号：US15232892
申请日：2016-08-10
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/4709 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/267 , A61K31/4015 , C07D207/08 , A61K31/40 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , A61K45/06 , C07D401/12
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 如说明书中所定义。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES](/abs-image/US/2014/08/28/US20140243312A1/abs.jpg.150x150.jpg)
公开(公告)号：US20140243312A1
公开(公告)日：2014-08-28
申请号：US14183946
申请日：2014-02-19
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez
IPC: C07D487/04
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物，它们用作Janus Kinase（JAK）抑制剂，以及含有它们的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.034 seconds)
